Everything you need to know about What Predicts TMS Success? Key Factors That Influence Treatment Outcomes — how it works, what it costs, and how to find a provider who actually knows what they're doing.

Transcranial magnetic stimulation offers hope for many patients with depression who have not found relief through medications or therapy. However, TMS is not effective for everyone. Understanding the factors that predict treatment response can help patients and clinicians set realistic expectations, optimize treatment protocols, and make informed decisions about whether TMS is appropriate.

Treatment Response Rates: Setting the Baseline

Before examining predictors, it helps to understand the overall statistics. Across hundreds of clinical trials, approximately:

• 50-60% of patients show clinically significant improvement (response)
• 30-40% achieve remission (full or near-full symptom resolution)
• 40-50% do not respond adequately to a standard TMS course

These averages mask significant individual variation. Understanding what makes someone more or less likely to fall into the favorable outcomes is the focus of active research.

What You’ll Learn

• How age, treatment resistance level, and episode duration predict TMS response
• Why brain connectivity patterns matter more than clinical severity
• Which comorbidities improve or reduce TMS effectiveness
• How coil type, stimulation frequency, and neuronavigation affect outcomes
• What patients can do to optimize their chances of success

Patient Characteristics That Predict Response

Age

Age is one of the most consistent predictors of TMS response. Younger patients tend to respond better than older patients.

Why age matters:

• Neuroplasticity decreases with age, making it harder for the brain to form new connection patterns
• Older brains may have more accumulated neural “scarring” from years of depression
• Treatment-resistant depression often becomes more severe and less treatable over time
• Brain atrophy in older adults may affect stimulation field distribution

A 2018 analysis of over 2,000 patients found that those under 55 showed response rates approximately 10-15% higher than those over 65. However, many older patients still benefit substantially, and age alone should not disqualify someone from treatment.

Duration of Current Episode

The longer a depressive episode has persisted without treatment response, the less likely TMS is to be effective.

• Acute depression (less than 2 years): Best response rates
• Chronic depression (more than 2 years): Reduced response, but still significant benefits possible
• Lifelong depression: Lower response rates, may require more intensive protocols

This pattern reflects the neurobiological changes that occur with prolonged depression, including synaptic loss and network atrophy.

Number of Failed Medication Trials

TMS was originally studied in treatment-resistant depression, typically defined as failure of 1-2 adequate antidepressant trials. The more medications a patient has failed, the lower the expected TMS response.

The STAR*D paradox: While TMS was developed for treatment-resistant cases, patients who have failed only 1-2 medications respond better than those who have failed 5 or more. This may be because:

• Severe treatment resistance reflects fundamentally different neurobiology
• Extended medication exposure may alter neural circuits in ways that reduce TMS responsiveness
• Some patients’ depressions are inherently less responsive to neuromodulation

Patients with mild-to-moderate treatment resistance (1-3 failed trials) generally have the best TMS outcomes.

Brain Connectivity Patterns

Neuroimaging research has revealed that pre-treatment brain connectivity strongly predicts TMS response. This represents one of the most important advances in personalizing TMS treatment.

Predictors of good response:

• Strong baseline connectivity between the stimulation site (DLPFC) and other regions of the mood regulation network
• Balanced activity in prefrontal cortex circuits
• Normal baseline activity in the subcallosal cingulate cortex
• Intact structural connectivity on diffusion tensor imaging (DTI)

Predictors of poor response:

• Disconnected DLPFC from the rest of the mood network
• Hyperactivity in regions associated with rumination and worry
• Significant white matter damage disrupting signal transmission

Connectivity-guided TMS, where stimulation targets are personalized based on individual neuroimaging, has significantly improved response rates in clinical trials.

Comorbid Conditions

Conditions that reduce TMS response:

• Borderline personality disorder — emotional dysregulation may limit treatment engagement
• Active substance use disorders — ongoing alcohol or drug use affects brain function
• Significant anxiety disorders — comorbid anxiety may require modified protocols
• Psychotic features — TMS alone is not appropriate for psychotic depression
• Severe cognitive impairment — limits ability to engage with treatment

Conditions that do not preclude response:

• Anxiety symptoms without primary anxiety disorder — TMS often helps
• Migraine — may actually improve with TMS
• Chronic pain — TMS may benefit pain alongside depression

Genetic Factors

Emerging research suggests that genetic variations affect TMS response:

• BDNF (Brain-Derived Neurotrophic Factor) — The Val66Met polymorphism affects neuroplasticity and may predict TMS response
• Serotonin transporter gene (5-HTTLPR) — May influence antidepressant response to neuromodulation
• Other candidate genes related to synaptic plasticity and neurotransmitter function

While genetic testing is not yet standard practice, it may become a useful tool for predicting response.

Treatment Parameters That Affect Outcomes

Coil Type

Different coil geometries produce different stimulation patterns:

Figure-8 coils — Standard coils providing focal stimulation. Good for targeted DLPFC stimulation.

Double-cone coils — Provide deeper penetration, reaching subcortical structures. May be better for some anxiety presentations.

H-coils (Deep TMS) — FDA-cleared for depression, reach deeper structures with less focality. May benefit patients with thicker skulls or suboptimal response to focal coils.

Pulse configuration affects how the magnetic energy is delivered and may influence effectiveness.

Stimulation Frequency and Pattern

• Standard high-frequency (10 Hz) — Most evidence for left DLPFC stimulation
• Low-frequency (1 Hz) — Right DLPFC targeting for anxiety or mixed states
• Theta burst (iTBS) — Faster protocols with comparable efficacy to standard rTMS
• Intermittent theta burst — Current evidence suggests superior outcomes to standard protocols
• Bilateral stimulation — May benefit patients with mixed depression/anxiety

Treatment Intensity and Dose

Higher treatment intensity generally produces better outcomes:

• Motor threshold — 100-120% of motor threshold is standard; some evidence favors 120%
• Number of pulses per session — Higher pulse counts may improve response
• Number of sessions — Standard is 30-36 sessions; some patients benefit from more
• Session frequency — Daily sessions are standard; accelerated protocols (twice daily) may be more effective

Neuronavigation

Using MRI guidance to precisely target stimulation sites improves accuracy and may improve outcomes, particularly for personalized connectivity-guided protocols.

What Patients Can Do to Improve Their Chances

While some predictors are fixed, patients can optimize their treatment:

1. Choose an experienced provider — Centers performing high volumes of TMS tend to have better outcomes
2. Ensure adequate dosing — Don’t settle for lower doses if higher doses are tolerated
3. Complete the full course — Early discontinuation dramatically reduces response rates
4. Optimize concurrent medications — Some medications may enhance TMS; discuss with your provider
5. Engage in psychotherapy — CBT or other therapy during TMS may improve and maintain gains
6. Address sleep and lifestyle — Regular sleep, exercise, and nutrition support neuroplasticity

Realistic Expectations

Understanding what affects TMS success helps set appropriate expectations. TMS is:

• More effective than medications in head-to-head comparisons for treatment-resistant patients
• Not a cure — most patients need maintenance treatment eventually
• Variable — outcomes range from complete remission to no benefit
• Worth trying — even partial response can meaningfully improve quality of life

If you are considering TMS, discuss these predictive factors with your provider. A thorough evaluation should include assessment of your specific risk profile and optimization of treatment parameters for your individual situation.